✦ LIBER ✦

The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes

✍ Scribed by Jabbour, Elias; Garcia-Manero, Guillermo; Cornelison, A. Megan; Cortes, Jorge E.; Ravandi, Farhad; Daver, Naval; Kadia, Tapan; Teng, Angela; Kantarjian, Hagop

Book ID: 125834944
Publisher: Informa plc
Year: 2014
Tongue: English
Weight: 264 KB
Volume: 56
Category: Article
ISSN: 1042-8194
DOI: 10.3109/10428194.2014.914192

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long Term Effect of Decitabine (DAC) Dos

Long Term Effect of Decitabine (DAC) Dose Delay (DD) and Dose Reduction (DR) on Survival and Progression of Patients (pts) with Myelodysplastic Syndrome (MDS)

✍ Ghanem, Hady; Cornelison, A. Megan; Garcia-Manero, Guillermo; Kantarjian, Hagop; 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 54 KB

P-289 Effect of low-dose cytarabine and

P-289 Effect of low-dose cytarabine and aclarubicin in combination with decitabine on the outcome of patients with high-risk myelodysplastic syndromes

✍ Pian, S.; Duan, L.; Zhu, Y.; Hong, M.; Zhang, R.; Zhang, S.; Liu, P.; Lu, H.; Wu 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 91 KB

Retrospective Analysis of Prognostic Fac

Retrospective Analysis of Prognostic Factors Associated With Response and Overall Survival by Baseline Marrow Blast Percentage in Patients With Myelodysplastic Syndromes Treated With Decitabine

✍ Jabbour, Elias; Kantarjian, Hagop; O'Brien, Susan; Kadia, Tapan; Malik, Asifa; W 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 255 KB

The impact of hypomethylating agents on

The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes

✍ Rong Wang; Cary P. Gross; Kevin Frick; Xiao Xu; Jessica Long; Azra Raza; Naomi G 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 293 KB

P-181 Effect of availability of oral iro

P-181 Effect of availability of oral iron chelation therapy on initiation, duration, and dose adequacy in patients with myelodysplastic syndromes

✍ Zeidan, A.; Davidoff, A.; Hendrick, F.; Duong, V.; Stuart, B.; Baer, M.; Gore, S 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 67 KB

Effect of androgen therapy and anemia on

Effect of androgen therapy and anemia on serum erythropoietin levels in patients with aplastic anemia and myelodysplastic syndromes

✍ Piedras, Josefa; Hernández, Guadalupe; López-Karpovitch, Xavier 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB 👁 2 views

Immunoreactive serum erythropoietin (EPO) was measured in anemic and non-anemic patients with acquired non-severe aplastic anemia (AA; n = 22) and myelodysplastic syndromes (MDS; n = 31) receiving or not androgens to examine the effect of androgen therapy and anemia on EPO levels in these disorders.